Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO ‐0510-Reference-Cited by-同舟云学术

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO ‐0510

Published:2021-11-15 Issue:6 Volume:150 Page:1007-1017
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Högner Anica¹^ORCID,Al‐Batran Salah‐Eddin²,Siveke Jens T.³⁴⁵⁶,Lorenz Mario¹,Bartels Prisca¹,Breithaupt Kirstin¹⁷,Malfertheiner Peter⁸,Homann Nils⁹,Stein Alexander¹⁰,Gläser Dietrich¹¹,Tamm Ingo¹²,Hinke Axel¹³,Vogel Arndt¹⁴,Thuss‐Patience Peter¹,

Affiliation:

1. Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie Charité—Universitätsmedizin Berlin Berlin Germany

2. Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest Frankfurt Germany

3. II. Medizinische Klinik, Klinikum rechts der Isar Technische Universität München Munich Germany

4. Brückeninstitut für Experimentelle Tumortherapie Westdeutsches Tumorzentrum, Universitätsklinikum Essen Essen Germany

5. Abteilung für Translationale Onkologie Solider Tumore, Deutsches Konsortium für Translationale Krebsforschung (DKTK) Parnterstandort Essen Germany

6. Deutsches Krebsforschungszentrum (DKFZ) Heidelberg Germany

7. Palliativnetz Travebogen gGmbH Lübeck Germany

8. Klinik für Gastroenterologie, Hepatologie und Infektiologie Otto‐von‐Guericke‐Universität Magdeburg Germany

9. Medizinische Klinik II Klinikum Wolfsburg Wolfsburg Germany

10. Medizinische Klinik II Universitätsklinikum Hamburg‐Eppendorf Hamburg Germany

11. Klinik für Innere Medizin III Klinikum Südstadt Rostock Rostock Germany

12. Onkologische Schwerpunktpraxis Kurfürstendamm Berlin Germany

13. CCRC Cancer Clinical Research Consulting Düsseldorf Germany

14. Medizinische Hochschule Hannover Klinik für Gastroenterologie, Hepatologie und Endokrinologie Hannover Germany

Funder

GlaxoSmithKline foundation

Novartis

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33864

Reference35 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

3. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group

4. Chemotherapy for advanced gastric cancer;Wagner AD;Cochrane Database Syst Rev,2017

5. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects;Molecular Pharmaceutics;2024-06-18

2. Phase I trial of apatinib and paclitaxel+oxaliplatin+5‐FU/levoleucovorin for treatment‐naïve advanced gastric cancer;Cancer Science;2024-02-14

3. Identification and characterization of CLEC11A and its derived immune signature in gastric cancer;Frontiers in Immunology;2024-01-29

4. Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer;Critical Reviews in Oncology/Hematology;2023-11

5. First-Line Systemic Therapy Outcomes in Western Population with Locally Advanced and Metastatic Gastric Cancer—A Systematic Review;Gastroenterology Insights;2023-11-01